Q1 FY27 sales highlights: Immuron lifts quarterly sales 9% to $2.2 million
In its Q1 FY27 sales update for the quarter ending 30 September 2026, Immuron Limited (ASX: IMC; NASDAQ: IMRN) recorded global sales of $2.2 million. That was up 9% on the prior comparative period (pcp) and up 5% on the prior quarter.
The company described the result as double digit sales growth. All figures are unaudited and in Australian dollars.
Growth was recorded in three of the four reported lines, with Australia the largest contributor by value.
| Region | Q1 FY27 sales | vs pcp | vs prior quarter |
|---|---|---|---|
| Global | $2.2M | +9% | +5% |
| Australia | $1.8M | +14% | +12% |
| Canada | $0.1M | +286% | +63% |
| USA | $0.3M | -19% | -24% |
Key takeaways from the quarter:
- Global sales reached $2.2 million, up 9% on pcp.
- Australia delivered $1.8 million, up 14% on pcp and 12% on the prior quarter.
- Canada grew 286% on pcp to reach $0.1 million.
- The USA declined 19% on pcp to $0.3 million.
When big ASX news breaks, our subscribers know first
Australia: Travelan brand re-launch drives 14% growth
Immuron attributed the 14% Australian growth on pcp to the new Travelan brand re-launch, which included new packaging and associated brand communications. The company said these resonated strongly with consumers and were well received and supported by all the major pharmacy banner groups.
Travelan outpaces its category
Travelan was described as one of the fastest growing anti-diarrhoeals and digestive health brands in pharmacy, growing at 26.4% versus category growth of 5.3%. In the last 13 weeks, it also exceeded well-known brands such as Imodium in total pharmacy sales, based on IQVIA scan sales for the 13 weeks to 26 September 2026.
ProIBS distribution widens
Immuron continued to increase market penetration of ProIBS, which is now stocked by the largest wholesaler, Sigma, and is available in Amcal and DDS pharmacies. The company holds an exclusive distribution agreement with Calmino group AB for the territories of Australia and New Zealand.
What Travelan is and how it works
Travellers’ diarrhoea is generally defined as the passage of three or more unformed stools per 24 hours plus at least one additional symptom, such as nausea, vomiting or abdominal cramps. It develops while abroad or within 10 days of returning from resource-limited destinations.
Travelan is a tablet made from hyperimmune bovine antibodies. Taken with meals, the antibodies bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with the condition.
Its regulatory status varies by market:
- Australia: a listed medicine on the Australian Register for Therapeutic Goods.
- Canada: a licensed natural health product.
- United States: sold as a dietary supplement for digestive tract protection.
For investors, the Australian figures point to a differentiated product gaining share in a growing pharmacy category.
Investors weighing the clinical evidence behind the product can read our detailed coverage of the Travelan Phase 2 trial results, which covers the 50% reduction in ETEC-related adverse events and the missed primary endpoints.
Canada surges 286% while US softens
Canada momentum
Immuron attributed the 286% Canadian growth on pcp to increased brand awareness and product sampling at the Shoppers Drug Mart conferences in Toronto and Calgary. Shoppers Drug Mart is Canada’s largest drugstore chain, according to the company.
July 2026 was Travelan’s highest non-pipeline sales month in Canada. With quarterly sales of $0.1 million, the percentage gain reflects a small base.
US dip explained
US sales fell 19% on pcp, which Immuron linked to higher purchases during Amazon Prime Day in June 2026 and customs and logistics challenges that delayed replenishment of US inventory. The company said inventory is now replenished.
Sales were also down 24% on the prior quarter.
What happens next for Immuron in the US
Immuron said there is a positive outlook for the next quarter, citing the following sales events:
- Amazon Prime days in October, a stated sales opportunity for the company’s US business.
- Thanksgiving, Black Friday and Cyber Monday in November, which the company said support the positive outlook for the next quarter.
Beyond the commercial products, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection.
The IMM-529 partnering strategy is built around an FDA-cleared IND and an independent assessment projecting US$400 million in base case yearly revenue, with Pullan Consulting engaged to find a partner for the recurrent CDI program.
Want to Explore Immuron’s Travelan Growth Story?
Immuron lifted Q1 FY27 sales 9% to $2.2 million, powered by a 14% jump in Australia after the Travelan brand re-launch and a 286% surge in Canada. With IMM-529 also advancing towards partnering, the company is building momentum on both the commercial and clinical fronts.
Investors seeking deeper insight into the company’s products, pipeline and latest updates can visit the Immuron investor centre. Explore the full picture before the next quarter’s sales events get underway.